Raymond James View Skewed Scenarios On Absent Supportive Bid For This Animal Health Stock
Raymond James downgraded the rating on Covetrus Inc (NASDAQ:CVET) from Outperform to Market Perform and removed the prior $22 price target after the…
Morgan Stanley Maintains Equal-Weight on Covetrus, Raises Price Target to $21
Morgan Stanley maintains Covetrus (NASDAQ:CVET) with a Equal-Weight and raises the price target from $19 to $21.
66 Biggest Movers From Friday
Gainers
GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Covetrus: Q4 Earnings Insights
Covetrus (NASDAQ:CVET) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Covetrus beat estimated earnings by 4.0%, reporting an EPS of $0.26 versus an estimate of $0.25.